Clinical research
On October 14th, Amolyt Pharma announced the first dosing in its Phase I trial of AZP-3601 in healthy subjects, a momentous occasion capping off years of hard work in pre-clinical development. The drug aims to walk the biological tightrope in the management of hypoparathyroidism, a rare disease causing muscular pain and cognitive challenges.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Pfizer indicated yesterday that its Phase III clinical trial of 44,000 volunteers now needs fewer than 2,000 people to be fully enrolled.
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Treatment with FORMA Therapeutics’ investigational agent olutasidenib has shown promising efficacy and safety in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and mutations in isocitrate dehydrogenase 1 (IDH1m).
FibroGen presented data from two pooled analyses from its roxadustat global Phase III development program this weekend at the American Society of Nephrology Kidney Week 2020 Reimagined conference.
Days after the U.S. FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G). The analysis was presented at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting.
After nearly a month in limbo, AstraZeneca will resume Phase III testing of its COVID-19 vaccine candidate in the United States.
PRESS RELEASES